- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06097390
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III
February 5, 2024 updated by: Novo Nordisk A/S
A Study Investigating the Pharmacokinetic Properties When Dosing Different Formulations of Semaglutide to Healthy Male Participants - Oral Formulation III
In this study, a known medicine called 'semaglutide' will be tested in two different tablet versions.
The two tablets differ in the way these have been manufactured.
The aim of the study is to investigate the amount of active ingredient in the blood after dosing the different tablet versions.
Participants will receive one tablet version for 10 days (first treatment period) and the other version for 10 days (second treatment period).
The treatment arm participants will be assigned to is decided by chance.
The study will last for about 23 weeks for each participant.
The study will enroll healthy male participants.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Novo Nordisk
- Phone Number: (+1) 866-867-7178
- Email: clinicaltrials@novonordisk.com
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3P 3P1
- Recruiting
- Altasciences Clinical Company, Inc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Key inclusion criteria:
- Body mass index (BMI) between 22.0 and 31.9 kilograms per meter square (kg/m^2) (both inclusive) at screening.
- Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Key exclusion criteria:
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
- Use of prescription medicinal products or non-prescription drugs, except routine vitamins, topical medication not reaching the systemic circulation and occasional use of paracetamol (acetaminophen) and ibuprofen, within 14 days before screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence 1: Semaglutide J then Semaglutide K
Oral semaglutide J will be administered in treatment period 1 followed by semaglutide K in treatment period 2.
|
Oral administration
|
Experimental: Sequence 2: Semagultide K then Semaglutide J
Oral semaglutide K will be administered in treatment period 1 followed by semaglutide J in treatment period 2.
|
Oral administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adjusted AUC0-24h,sema; adjusted area under the semaglutide plasma concentration-time curve
Time Frame: From 0 to 24 hours after dosing on day 80 and 90
|
Measured in hour*nanomoles per liter (h*nmol/L).
|
From 0 to 24 hours after dosing on day 80 and 90
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adjusted Cmax,0-24h,sema; adjusted maximum observed semaglutide plasma concentration
Time Frame: From 0 to 24 hours after dosing on day 80 and 90
|
Measured in nanomoles per liter (nmol/L).
|
From 0 to 24 hours after dosing on day 80 and 90
|
Adjusted tmax,0-24h,sema; time to adjusted maximum observed semaglutide plasma concentration
Time Frame: From 0 to 24 hours after dosing on day 80 and 90
|
Measured in hours.
|
From 0 to 24 hours after dosing on day 80 and 90
|
t½,sema; the terminal half-life of semaglutide
Time Frame: From 0 to 840 hours after dosing on day 90
|
Measured in hours.
|
From 0 to 840 hours after dosing on day 90
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 28, 2023
Primary Completion (Estimated)
March 24, 2024
Study Completion (Estimated)
March 24, 2024
Study Registration Dates
First Submitted
October 18, 2023
First Submitted That Met QC Criteria
October 18, 2023
First Posted (Actual)
October 24, 2023
Study Record Updates
Last Update Posted (Estimated)
February 7, 2024
Last Update Submitted That Met QC Criteria
February 5, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- NN9501-4924
- U1111-1289-1040 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Participants
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
Insmed IncorporatedRecruitingHealthy ParticipantsUnited States
-
Aeovian Pharmaceuticals, Inc.RecruitingHealthy ParticipantsAustralia
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingHealthy ParticipantsChina
-
CelgeneNot yet recruitingHealthy ParticipantsUnited States
-
Bristol-Myers SquibbNot yet recruiting
-
AstraZenecaParexelRecruiting
-
ProMis Neurosciences, IncRecruiting
-
Novo Nordisk A/SRecruiting
-
Alexion Pharmaceuticals, Inc.Recruiting
Clinical Trials on Semaglutide
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
-
Novo Nordisk A/SCompletedObesityUnited States, Israel, United Kingdom, Denmark, Germany, Netherlands, Canada, Argentina, Czechia, Hungary, Poland, Spain, Australia
-
Novo Nordisk A/SCompletedObesity | Diabetes Mellitus, Type 2 | OverweightKorea, Republic of, Hong Kong, Brazil, China
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States
-
Novo Nordisk A/SRecruiting
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Novo Nordisk A/SCompletedType 2 Diabetes | Healthy VolunteersUnited States, Canada
-
Novo Nordisk A/SCompleted
-
Sansum Diabetes Research InstituteNovo Nordisk A/STerminatedDiabetes Mellitus, Type 2 | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, Italy, Spain, Canada, Hungary